• 1
    Moreno-Otero R, Garcia-Monzon C, Garcia-Buey L. Pathogenesis of autoimmune liver diseases. In: ArroyoV, BoschJ, BrugueraM, (Eds) Pathogenesis of Autoimmune Liver Diseases. Barcelona: Masson S. A.;1997:p.219 29.
  • 2
    Kaplan MM. Primary biliary cirrhosis. Adv Intern Med 1987;32:359 77.
  • 3
    Moreno-Otero R, Lisker-Melman M, Jones EA. Primary biliary cirrhosis. Med Clin N Am 1989;73:911 29.
  • 4
    Metcalf JV, Mitchison HC, Palmer J, Jones DE, Bassendine ME, James O. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399 402.DOI: 10.1016/s0140-6736(96)04410-8
  • 5
    Nishio A, Van de Water J, Leung PS, Joplin R, Neuberger JM, Lake J et al. Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997;25:1085 9.
  • 6
    Reynoso-Paz S, Leung PS, Van De Water J, Tanaka A, Munoz S, Bass N et al. Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis. Hepatology 2000;31:24 9.
  • 7
    Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997;25:6 11.
  • 8
    Lindgren S & Eriksson S. IgM in primary biliary cirrhosis: Physicochemical and complement activating properties. J Lab Clin Med 1982;99:636 45.
  • 9
    Heathcote J. The clinical expression of primary biliary cirrhosis. Semin Liver Dis 1997;17:23 33.
  • 10
    Nakanuma Y, Yasoshima M, Tsuneyama K, Harada K. Histopathology of primary biliary cirrhosis with emphasis on expression of adhesion molecules. Semin Liver Dis 1997;17:35 47.
  • 11
    Jones DE. T-cell autoimmunity in primary biliary cirrhosis. Clin Sci (Colch) 1996;91:551 8.
  • 12
    Garcia-Buey L, Garcia-Monzon C, Santander C, Majano PL, Garcia-Sanchez A, Moreno-Otero R. Intrahepatic expression of adhesion and antigen recognition molecules in primary biliary cirrhosis. Hepatology 1994;20:148A.
  • 13
    Moreno-Otero R, Civeira MP, Suou T, Kanof ME, James SP, Jones EA. Reduced numbers of CD8+ T cells and B-cell expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis. Hepato-Gastroenterol 1994;41:239 43.
  • 14
    Moreno-Otero R, Murakawa Y, Kanof ME, Civeira MP, Jones EA, James SP. Defective proliferation and regulatory function of CD4+ T cells bearing Leu-8 homing receptor in primary biliary cirrhosis: phorbol myristate acetate enhances T-cell function. Dig Dis Sci 1994;39:1329 36.
  • 15
    Gershwin ME, Coppel RL, Mackay IR. Primary biliary cirrhosis and mitochondrial autoantigens – insights from molecular biology. Hepatology 1988;8:147 51.
  • 16
    Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988;1:1067 70.
  • 17
    Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988;141:2321 4.
  • 18
    Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988;85:8654 8.
  • 19
    Fregeau DR, Davis PA, Danner DJ, Ansari A, Coppel RL, Dickson ER et al. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J Immunol 1989;142:3815 20.
  • 20
    Fregeau DR, Roche TE, Davis PA, Coppel R, Gershwin ME. Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J Immunol 1990;144:1671 6.
  • 21
    Surh CD, Roche TE, Danner DJ, Ansari A, Coppel RL, Prindiville T et al. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology 1989;10:127 33.
  • 22
    Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin Liver Dis 1997;17:49 60.
  • 23
    Dubel L, Tanaka A, Leung PS, Van de Water J, Coppel R, Roche T et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3 bp) and the glycine cleavage proteins in primary biliary cirrhosis . Hepatology 1999;29:1013 8.
  • 24
    Chen QY, Mackay IR, Fida S, Myers MA, Rowley MJ. Natural and disease associated autoantibodies to the autoantigen, dihydrolipoamide acetyltransferase, recognize different epitopes. J Autoimmun 1998;11:151 61.DOI: 10.1006/jaut.1998.0188
  • 25
    Surh CD, Coppel R, Gershwin ME. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J Immunol 1990;144:3367 74.
  • 26
    Leung PS, Chuang DT, Wynn RM, Cha S, Danner DJ, Ansari A et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 1995;22:505 13.
  • 27
    Moteki S, Leung PS, Dickson ER, Van Thiel DH, Galperin C, Buch T et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996;23:436 44.
  • 28
    Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, Nakanuma Y et al. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998;161:5157 63.
  • 29
    Courvalin JC & Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997;17:79 90.
  • 30
    Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996;110:840 7.
  • 31
    Szostecki C, Guldner HH, Will H. Autoantibodies against ‘nuclear dots’ in primary biliary cirrhosis. Semin Liver Dis 1997;17:71 8.
  • 32
    Neuberger J & Thomson R. PBC and AMA – what is the connection? Hepatology 1999;29:271 6.
  • 33
    Leung PS, Van de Water J, Coppel RL, Nakanuma Y, Munoz S, Gershwin ME. Molecular aspects and the pathological basis of primary biliary cirrhosis. J Autoimmun 1996;9:119 28.DOI: 10.1006/jaut.1996.0015
  • 34
    Tsuneyama K, Van de Water J, Leung PS, Cha S, Nakanuma Y, Kaplan M et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995;21:1031 7.
  • 35
    Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998;352:1595 6.DOI: 10.1016/s0140-6736(98)00064-6
  • 36
    Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997;100:25 31.
  • 37
    Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993;91:2653 64.
  • 38
    Leon MP, Bassendine MF, Wilson JL, Ali S, Thick M, Kirby JA. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology 1996;24:561 7.
  • 39
    Meuer SC, Moebius U, Manns MM, Dienes HP, Ramadori G, Hess G et al. Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. Eur J Immunol 1988;18:1447 52.
  • 40
    Harada K, Tsuneyama K, Hiramatsu K, Nakanuma Y. Significance of CD30-positive lymphocytes in livers in primary biliary cirrhosis. J Gastroenterol Hepatol 1999;14:1197 202.
  • 41
    Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gerschwin ME et al. Mimicry peptides of human PDC-E2, 163–176 peptide, the immunodominant T–cell epitope of primary biliary cirrhosis. Hepatology 2000;31 :1212–6.
  • 42
    Van der Water J, Ansari AA, Surh CD, Coppel R, Roche T, Bonkovsky H et al. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991;146:89 94.
  • 43
    Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998;102:1831 40.
  • 44
    Van de Water J, Ansari A, Prindiville T, Coppel RL, Ricalton N, Kotzin BL et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995;181:723 33.
  • 45
    Gerschwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210 25.
  • 46
    Jones DEJ, Palmer JM, Yeaman SJ, Kirby JA, Bassendine MF. Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis – a murine model of primary biliary cirrhosis. Hepatology 1999;30:65 70.
  • 47
    Yeaman SJ, Kirby JA, Jones DE. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev 2000;174:238 49.
  • 48
    Yasoshima M, Tsuneyama K, Harada K, Sasaki M, Gershwin ME, Nakanuma Y. Immunohistochemical analysis of cell-matrix adhesion molecules and their ligands in the portal tracts of primary biliary cirrhosis. J Pathol 2000;190:93 9.DOI: 10.1002/(sici)1096-9896(200001)190:1<93::aid-path507>;2-a
  • 49
    Iwata M, Harada K, Kono N, Kaneko S, Kobayashi K, Nakanuma Y. Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis. Hum Pathol 2000;31:179 84.
  • 50
    Iwata M, Harada K, Hiramatsu K, Tsuneyama K, Kaneko S, Kobayashi K et al. Fas ligand expressing mononuclear cells around intrahepatic bile ducts co-express CD68 in primary biliary cirrhosis. Liver 2000;20:129 35.
  • 51
    Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998;351:1620 4.DOI: 10.1016/s0140-6736(97)10290-2
  • 52
    Mason AL, Xu L, Guo L, Garry RF. Retroviruses in autoimmune liver disease: genetic or environmental agents? Arch Immunol Ther Exp 1999;47:289 97.
  • 53
    Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB et al. Are infectious agents involved in primary biliary cirrhosis? A PCR Approach. J Hepatol 1999;31:664 71.
  • 54
    Agarwal K, Jones DE, Bassendine MF. Genetic susceptibility to primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:603 6.
  • 55
    Johnston DE, Kaplan MM, Miller KB, Connors CM, Milford EL. Histocompatibility antigens in primary biliary cirrhosis. Am J Gastroenterol 1987;82:1127 9.
  • 56
    Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology 1994;20:225 39.
  • 57
    Gordon MA, Oppenheim E, Camp NJ, Di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999;31:242 7.
  • 58
    Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538 41.
  • 59
    Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342 7.
  • 60
    Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005 13.
  • 61
    Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO. James of. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992;15:336 44.
  • 62
    Ponsioen CI & Tytgat GN. Primary sclerosing cholangitis: a clinical review. Am J Gastroenterol 1998;93:515 23.
    Direct Link:
  • 63
    Rosen CB, Nagorney DM, Wiesner RH, Coffey Rj Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21 5.
  • 64
    Lee YM & Kaplan MM. Primary sclerosing cholangitis. New Engl J Med 1995;332:924 33.
  • 65
    Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10:430 6.
  • 66
    Nilsson HO, Castedal M, Olsson R, Wadstrom T. Detection of Helicobacter in the liver of patients with chronic cholestatic liver diseases. J Physiol Pharmacol 1999;50:875 82.
  • 67
    Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072 6.
  • 68
    Nilsson I, Lindgren S, Eriksson S, Wadstrom T. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease. Gut 2000;46:410 4.
  • 69
    Narayanan Menon KV & Wiesner RH. Etiology and natural history of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg 1999;6:343 51.
  • 70
    Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987;5:8 13.
  • 71
    Cello JP. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 1989;86:539 46.
  • 72
    Lautenschlager I, Hockerstedt K, Jalanko H, Loginov R, Salmela K, Taskinen E et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997;25:190 4.
  • 73
    Bernal W, Moloney M, Underhill J, Donaldson PT. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol 1999;30:237 41.
  • 74
    Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, IgG subclass. Gut 1996;38:387 9.
  • 75
    Roozendaal C, Van Milligen de Wit AW, Haagsma EB, Horst G, Schwarze C, Peter HH et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 1998;105:393 9.DOI: 10.1016/s0002-9343(98)00294-0
  • 76
    Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998;28:332 40.
  • 77
    Orth T, Kellner R, Diekmann O, Faust J, Meyer zum Buschenfelde KH, Mayet WJ. Identification anc characterisation of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998;112:507 15.DOI: 10.1046/j.1365-2249.1998.00583.x
  • 78
    Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182 7.
  • 79
    Snook JA, Chapman RW, Sachdev GK, Heryet A, Kelly PM, Fleming KA et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989;9:36 41.
  • 80
    Martins EB, Graham AK, Chapman RW, Fleming KA. Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology 1996;23:988 93.
  • 81
    Broome U, Glaumann H, Hultcrantz R, Forsum U. Distribution of HLA-DR, HLA-DP.HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand J Gastroenterol 1990;25:54 8.
  • 82
    Chapman RW, Kelly PM, Heryet A, Jewell DP, Fleming KA. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988;29:422 7.
  • 83
    Tsuneyama K, Harada K, Yasoshima M, Kaji K, Gershwin ME, Nakanuma Y. Expression of co-stimulatory factor B7–2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis: an immunohistochemical study. J Pathol 1998;186:126 30.DOI: 10.1002/(sici)1096-9896(1998100)186:2<126::aid-path167>;2-1
  • 84
    Ponsioen CY, Kuiper H, Ten Kate FJ, Van Milligen de Wit M, Van Deventer SJ, Tytgat GN. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1999;11:769 74.
  • 85
    Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994;35:260 5.
  • 86
    Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994;18:91 9.
  • 87
    Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995;40:1232 42.
  • 88
    Kinoshita H, Omagari K, Whittingham S, Kato Y, Ishibashi H, Sugi K et al. Autoimmune cholangitis and primary biliary cirrhosis – an autoimmune enigma. Liver 1999;19:122 8.
  • 89
    Nakajima M, Shimizu H, Miyazaki A, Watanabe S, Kitami N, Sato N. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis? J Gastroenterol 1999;34:607 12.DOI: 10.1007/s005350050380
  • 90
    Gordon SC, Quattrociocchi-Longe TM, Khan BA, Kodali VP, Chen J, Silverman AL et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995;108:1802 9.
  • 91
    Romero Gomez M, Wichmann I, Otero Fernandez MA, Suarez Garcia E, Grande L, Nunez J Et Al. Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis. Gastroenterol Hepatol 1999;22:11 3.
  • 92
    Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol 1998;93:1334 9.
    Direct Link:
  • 93
    Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10 5.
  • 94
    Kloppel G, Seifert G, Lindner H, Dammermann R, Sack HJ, Berg PA. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat 1977;373:143 60.
  • 95
    Lohse AW, Zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterisation of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078 84.
  • 96
    Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 1992;16:1128 36.
  • 97
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360 5.
  • 98
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296 301.
  • 99
    Mieli-Vergani G, Lobo-Yeo A, McFarlane BM, McFarlane IG, Mowat AP, Vergani D. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology 1989;9:198 203.
  • 100
    McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93:777 84.
    Direct Link:
  • 101
    Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699 705.
  • 102
    Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369 76.